SCHEMBL24252969

SCHEMBL24252969

COc1ccc(CNc2cnnc3cc(B4OC(C)(C)C(C)(C)O4)ccc23)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.41
APLNR P35414 1/20 0.39
CYP1A2 P05177 11/20 0.39
CYP3A4 P08684 11/20 0.39
CYP2D6 P10635 11/20 0.39
CYP2C19 P33261 10/20 0.39
TSHR P16473 8/20 0.39
HSD17B10 Q99714 7/20 0.39
CLK4 Q9HAZ1 7/20 0.39
CYP2C9 P11712 6/20 0.39
LMNA P02545 5/20 0.39
USP2 O75604 5/20 0.39
DHFR P00374 1/20 0.39
MAPK1 P28482 3/20 0.38
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38
SNCA P37840 1/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30462772 1.00 KDM4C (0.41) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL24252791 0.92 CYP1A2 (0.41) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30467683 0.92 CYP1A2 (0.41) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30467795 0.90 CYP1A2 (0.38) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24252831 0.90 CYP1A2 (0.38) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL26779863 0.87 CYP1A2 (0.38) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL25246451 0.85 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL24252747 0.84 CYP1A2 (0.34) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30467644 0.83 KDM4C (0.36) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24252881 0.83 KDM4C (0.36) KDM4CCYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH KDM4C 3892/4885APLNR 964/4885CYP1A2 4150/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 KDM4C 4654/4885APLNR 490/4885CYP1A2 3838/4885
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.